Celltrion to break ground on CDMO plant in 2025: Chairman Seo

South Korea’s leading biosimilar developer Celltrion Inc. will break ground on its first contract development and manufacturing organization (...
South Korea’s leading biosimilar developer Celltrion Inc. will break ground on its first contract development and manufacturing organization (...
South Korea’s National Pension Service (NPS) Chief Investment Officer Seo Won-joo has visited Japan and Singapore on his first overseas busine...
Sindoh Co., a leading manufacturer of multi-functional printers in South Korea, is set to tap an investment banking expert as its chief executive. W...
South Korea’s biosimilar drugmaker Celltrion group on Monday moved one step closer to the planned combination of its three major affiliates wi...
South Korean drug giant Celltrion Group will consider listing its holding company if necessary, after it completes the merger of three affiliates &n...
South Korean biosimilar giant Celltrion Group’s founder Seo Jung-jin has returned to management two years after his departure, pledging to mer...
Celltrion Inc., South Korea’s largest biosimilar maker, said on Tuesday it has studied a possible acquisition of the biopharma solutions unit ...
South Korea’s biosimilar giant Celltrion Group’s founder and Honorary Chairman Seo Jung-jin is readying to return to management just two...
National Pension Service (NPS) of South Korea, the world's third-largest pension fund, has tapped Seo Won-joo as the new chief investment officer, a...
South Korea’s National Pension Service (NPS), the world’s third-largest pension fund managing 917.2 trillion won ($692 billion) in asset...